These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23719087)

  • 1. Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.
    Han JH; Nachamkin I; Tolomeo P; Mao X; Bilker WB; Lautenbach E
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):491-6. PubMed ID: 23719087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.
    Lautenbach E; Metlay JP; Mao X; Han X; Fishman NO; Bilker WB; Tolomeo P; Wheeler M; Nachamkin I
    Clin Infect Dis; 2010 Aug; 51(3):280-5. PubMed ID: 20597679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli.
    Han JH; Garrigan C; Johnston B; Nachamkin I; Clabots C; Bilker WB; Santana E; Tolomeo P; Maslow J; Myers J; Carson L; Lautenbach E; Johnson JR;
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):275-280. PubMed ID: 27939288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.
    Lautenbach E; Fishman NO; Metlay JP; Mao X; Bilker WB; Tolomeo P; Nachamkin I
    J Infect Dis; 2006 Jul; 194(1):79-85. PubMed ID: 16741885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of outpatient fecal colonization due to Escherichia coli Isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from the hospital.
    Lautenbach E; Tolomeo P; Mao X; Fishman NO; Metlay JP; Bilker WB; Nachamkin I
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3939-43. PubMed ID: 16982789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates.
    Ríos E; López MC; Rodríguez-Avial I; Pena I; Picazo JJ
    Microb Drug Resist; 2015 Oct; 21(5):512-5. PubMed ID: 25945693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.
    Han JH; Bilker WB; Nachamkin I; Tolomeo P; Mao X; Fishman NO; Lautenbach E
    Infect Control Hosp Epidemiol; 2013 Oct; 34(10):1070-6. PubMed ID: 24018924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry.
    Vanni M; Meucci V; Tognetti R; Cagnardi P; Montesissa C; Piccirillo A; Rossi AM; Di Bello D; Intorre L
    Poult Sci; 2014 Apr; 93(4):856-63. PubMed ID: 24706962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence and maintenance of multidrug-resistant Escherichia coli of canine origin harbouring a blaCMY-2-IncI1/ST65 plasmid and topoisomerase mutations.
    Vingopoulou EI; Siarkou VI; Batzias G; Kaltsogianni F; Sianou E; Tzavaras I; Koutinas A; Saridomichelakis MN; Sofianou D; Tzelepi E; Miriagou V
    J Antimicrob Chemother; 2014 Aug; 69(8):2076-80. PubMed ID: 24722836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates.
    Chang TM; Lu PL; Li HH; Chang CY; Chen TC; Chang LL
    J Chemother; 2007 Oct; 19(5):488-94. PubMed ID: 18073146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
    Drago L; Nicola L; Mattina R; De Vecchi E
    BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
    Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
    J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns.
    Takahashi A; Muratani T; Yasuda M; Takahashi S; Monden K; Ishikawa K; Kiyota H; Arakawa S; Matsumoto T; Shima H; Kurazono H; Yamamoto S
    J Clin Microbiol; 2009 Mar; 47(3):791-5. PubMed ID: 19158256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
    Yasufuku T; Shigemura K; Shirakawa T; Nakano Y; Tanaka K; Arakawa S; Kinoshita S; Nishimura K; Kawabata M; Fujisawa M
    Scand J Infect Dis; 2011 Feb; 43(2):83-8. PubMed ID: 20942776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli.
    Han JH; Nachamkin I; Tolomeo P; Mao X; Bilker WB; Lautenbach E
    J Infect Dis; 2012 Nov; 206(10):1597-603. PubMed ID: 22966123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of fluoroquinolone-resistant Escherichia coli strains isolated from urine clinical samples.
    Dehbanipour R; Khanahmad H; Sedighi M; Bialvaei AZ; Faghri J
    J Prev Med Hyg; 2019 Mar; 60(1):E25-E30. PubMed ID: 31041407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.
    Sorlozano A; Gutierrez J; Jimenez A; de Dios Luna J; Martínez JL
    J Clin Microbiol; 2007 Aug; 45(8):2740-2. PubMed ID: 17567787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.